Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023
December 13 2022 - 8:00AM
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the
“Company”), the developer of the innovative alpha-radiation cancer
therapy Alpha DaRT™, announced today that the Company plans to
present at the Biotech Showcase™ and host institutional investor
meetings at this event, as well as at the LifeSci Partners
Corporate Access Event. Both in-person events are taking place in
parallel with the 41st Annual J.P. Morgan Healthcare Conference
which will be held January 9-12, 2023 in San Francisco, California.
Biotech Showcase:Raphi Levy,
Chief Financial Officer, will provide an overview of the Company,
including its Alpha DaRT technology, recent pre-clinical and
clinical progress, and upcoming clinical trials including its U.S.
multi-center pivotal trial in recurrent cutaneous squamous cell
carcinoma. Uzi Sofer, CEO of Alpha Tau and Raphi Levy will also
host 1x1 institutional investor meetings.
Date/Time: Monday January 9,
2023, at 3 pm PTLocation: Hilton San Francisco
Union Square in San Francisco; Yosemite A (Ballroom Level)To
schedule a meeting, investors can register on the Biotech Showcase
website
LifeSci Partners Corporate Access
Event:Uzi Sofer, CEO and Raphi Levy, CFO will be hosting
1x1 institutional investor meetings.
Date: Tuesday, January 10,
2023Location: Beacon Grand Hotel in San
FranciscoTo schedule a meeting on the online system managed by
LifeSci Partners, please click here to register for the
conference.
About Alpha DaRT™
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is
designed to enable highly potent and conformal alpha-irradiation of
solid tumors by intratumoral delivery of radium-224 impregnated
sources. When the radium decays, its short-lived daughters are
released from the sources and disperse while emitting high-energy
alpha particles with the goal of destroying the tumor. Since the
alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims
to mainly affect the tumor, and to spare the healthy tissue around
it.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company
that focuses on research, development, and potential
commercialization of the Alpha DaRT for the treatment of solid
tumors. The technology was initially developed by Prof. Itzhak
Kelson and Prof. Yona Keisari from Tel Aviv University.
Investor Relations Contact
IR@alphatau.com
Alpha Tau Medical (NASDAQ:DRTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alpha Tau Medical (NASDAQ:DRTS)
Historical Stock Chart
From Jul 2023 to Jul 2024